 Cabaletta Bio Inc NASDAQ: CABA presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris mPV, a blistering skin disease that affects mucous membranes. No dose-limiting toxicities were observed within three months. 